This is a working overview of growth hormone secretagogue, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic pentapeptide | Growth hormone secretagogue family |
| Molecular mass | Approximately 711.9 Da | Free base, calculated value |
| Receptor target | GHS-R1a, the ghrelin receptor | Agonist activity reported |
| Sequence | Aib-His-D-2-Nal-D-Phe-Lys-NH2 | C-terminal amide |
| Reported selectivity | Little change in ACTH, cortisol, prolactin | Based mainly on animal data |
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
Long-term storage of the dry powder is typically at minus twenty degrees Celsius or lower, protected from light and moisture. Solutions are commonly kept frozen and thawed only once, because repeated freeze-thaw cycles can promote aggregation and loss of measurable peptide content. Buffers near neutral pH are preferred over strongly acidic or strongly basic conditions. Shipping at ambient temperature is acceptable for short periods when the powder remains sealed and desiccated.
The flesh of the [black] bear is savoury, but rather luscious, and tastes not unlike pork. It was once so common an article of food in New-York as to have given the name of Bear Market to one of the principal markets of the city. Theodore Roosevelt likened the flesh of young American black bears to that of pork, and not as coarse or flavorless as the meat of grizzly bears. The most favored cuts are concentrated in the legs and loins. Meat from the neck, front legs and shoulders is usually ground into minced meat or used for stews and casseroles. Keeping the fat on tends to give the meat a strong flavor. As American black bears can have trichinosis, cooking temperatures need to be high in order to kill the parasites. Bear fat was once valued as a cosmetic article that promoted hair growth and gloss. The fat most favored for this purpose was the hard white fat found in the body's interior. As only a small portion of this fat could be harvested for this purpose, the oil was often mixed with large quantities of hog lard. However, animal rights activism over the last decade has slowed the harvest of these animals; therefore the lard from bears has not been used in recent years for the purpose of cosmetics.
Denaturing gels are run under conditions that disrupt the natural structure of the analyte, causing it to unfold into a linear chain. Thus, the mobility of each macromolecule depends only on its linear length and its mass-to-charge ratio. Thus, the secondary, tertiary, and quaternary levels of biomolecular structure are disrupted, leaving only the primary structure to be analyzed. Nucleic acids are often denatured by including urea in the buffer, while proteins are denatured using sodium dodecyl sulfate, usually as part of the SDS-PAGE process. For full denaturation of proteins, it is also necessary to reduce the covalent disulfide bonds that stabilize their tertiary and quaternary structure, a method called reducing PAGE. Reducing conditions are usually maintained by the addition of beta-mercaptoethanol or dithiothreitol. For a general analysis of protein samples, reducing PAGE is the most common form of protein electrophoresis. Denaturing conditions are necessary for proper estimation of molecular weight of RNA. RNA is able to form more intramolecular interactions than DNA which may result in change of its electrophoretic mobility. Urea, DMSO and glyoxal are the most often used denaturing agents to disrupt RNA structure. Originally, highly toxic methylmercury hydroxide was often used in denaturing RNA electrophoresis, but it may be method of choice for some samples. Denaturing gel electrophoresis is used in the DNA and RNA banding pattern-based methods temperature gradient gel electrophoresis (TGGE) and denaturing gradient gel electrophoresis (DGGE).
== Uses == PPG is used in many polyurethane formulations. Synthesis of waterborne polymers has been a feature with this substance. As the basic building block is propylene oxide, there are 3 carbons per oxygen on the backbone. This confers some degree of water miscibility though not as good as ethylene oxide-based molecules. It is used to synthesize the epoxy reactive diluent and flexibilizer, Poly(propylene glycol) diglycidyl ether. Another use of PPG is as a surfactant, wetting agent and dispersant in leather finishing. PPG is also employed as a reference and calibrant in mass spectrometry and HPLC. PPG and derivatives may be used as defoamers in drilling and other applications. It is also used as a primary ingredient in the making of paintballs. It has been evaluated as a corrosion inhibitor.
Senate Minority Leader Chuck Schumer criticized the investigation for undermining the Federal Reserve's independence and suggested that the investigation was being done to make Powell a scapegoat for public disapproval of Trump's handling of the U.S. economy and the administration's trade policies. After Trump announced that he would nominate Warsh to replace Powell on January 30, Tillis stated that he will oppose Warsh's nomination until the investigation into Powell is "fully and transparently resolved." Since the Senate Banking Committee's composition currently includes 13 Republicans and 11 Democrats, Tillis has the ability to block the committee from voting to advance Warsh's nomination to a full Senate confirmation vote. John Thune has said that Warsh will "probably not" be confirmed without support from Tillis. On February 4, Tillis, who is not seeking reelection in 2026, subsequently said that he will block Warsh's nomination for the remainder of the 119th United States Congress if the investigation continues until his term expires in January 2027, while the day before, Senate Democrats sitting on the Banking Committee called for a delay to the nomination until both the Powell investigation and the investigation of Lisa Cook were both ended. Tillis stated the previous September that he would not consider any replacement for Cook until the litigation was resolved.
=== Protein delivery === The development of therapeutic proteins that has presented a valuable method to treat diseases is limited by low efficiency of traditional delivery methods. The evaluation of cytosolic delivery of CPP linked proteins has been found to be prone to artifacts and therefore requires the use of evaluation methods that distinguish true cytosolic delivery from cell surface attached or endosomally entrapped CPP-proteins. Recently, several methods using CPPs as vehicles to deliver biologically active, full-length proteins into living cells and animals have been reported. Several groups have successfully delivered CPP fused proteins in vitro. TAT was able to deliver different proteins, such as horseradish peroxidase and RNase A across cell membrane into the cytoplasm in different cell lines in vitro. The size range of proteins with effective delivery is from 30kDa to 120-150kDa. In one study, TAT-fused proteins are rapidly internalized by lipid raft−dependent macropinocytosis using a transducible TAT−Cre recombinase reporter assay on live cells. In another study, a TAT-fused protein was delivered into mitochondria of breast cancer cells and decreased the survival of breast cancer cells, which showed capability of TAT-fusion proteins to modulate mitochondrial function and cell survival. Moreover, cR10, a cyclic poly-arginine CPP, enabled the endocytose independent transduction of antigen binding proteins through the cellular membrane with immediate bioavailability.
Sources: en.wikipedia.org
CPA is available in the form of oral tablets alone (higher-dose; 10 mg, 50 mg, 100 mg) or in combination with ethinylestradiol or estradiol valerate (low-dose; 1 or 2 mg CPA) and in the form of ampoules for intramuscular injection (higher-dose; 100 mg/mL, 300 mg/3 mL; brand name Androcur Depot). The higher-dose formulations are used to treat prostate cancer and certain other androgen-related indications while the low-dose formulations which also have an estrogen are used as combined birth control pills and are used in menopausal hormone therapy for the treatment of menopausal symptoms.
=== Legal status === Eptinezumab was approved for medical use in the United States in February 2020. In November 2021, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the granting of a marketing authorization for the medicinal product Vyepti, intended for the prophylaxis of migraine. The applicant for this medicinal product is H. Lundbeck A/S. Eptinezumab was approved for medical use in the European Union in January 2022.
=== Laboratory workup === Laboratory tests should focus on ruling out metabolic conditions that may mimic TIA (e.g., low blood sugar), in addition to further evaluating a patient's risk factors for ischemic events. All patients should receive a complete blood count with platelet count, blood glucose, basic metabolic panel, prothrombin time/international normalized ratio, and activated partial thromboplastin time as part of their initial workup. These tests help with screening for bleeding or hypercoagulable conditions. Other lab tests, such as a full hypercoagulable state workup or serum drug screening, should be considered based on the clinical situation and factors, such as the age of the patient and family history. A fasting lipid panel is also appropriate to thoroughly evaluate the patient's risk for atherosclerotic disease and ischemic events in the future. Other lab tests may be indicated based on the history and presentation; such as obtaining inflammatory markers (erythrocyte sedimentation rate and C-reactive protein) to evaluate for giant cell arteritis (which can mimic a TIA) in those presenting with headaches and monocular blindness.
The stronger the interactions between the polar analyte and the polar stationary phase (relative to the mobile phase) the longer the elution time. The interaction strength depends on the functional groups part of the analyte molecular structure, with more polarized groups (e.g., hydroxyl-) and groups capable of hydrogen bonding inducing more retention. Coulombic (electrostatic) interactions can also increase retention. Use of more polar solvents in the mobile phase will decrease the retention time of the analytes, whereas more hydrophobic solvents tend to increase retention times.
Sources: en.wikipedia.org
°C), which aligns well with modeled results of methane formation temperature and yield. However, some thermogenic methane samples have clumped-isotope temperatures that are unrealistically high. Possible explanations for exceedingly high clumped isotope temperatures include natural gas migration after formation, mixing effect, and kinetic isotope effect of secondary cracking.
==== Mechanism of action ==== Nabilone weakly stimulates cannabinoid receptor 1(CBR1) and cannabinoid receptor 2 (CBR2) in the central nervous system. It reduces vomiting mainly by interacting with CBR1. Nabilone shares some similarity with tetrahydrocannabinol (THC) in terms of chemical structure, but nabilone is also considered to be twice as active as THC.
=== Articles === As of 2025, Google Scholar reports that he has been cited 300,459 times, has an h-index of 207 and an i10-index of 1,261. Bhatt has authored or co-authored over 2,250 publications and has been listed by the Web of Science Group as a highly cited researcher from 2014 to 2024. Bhatt's most cited, peer-reviewed articles reported by Google Scholar include:
Sources: en.wikipedia.org
Ipamorelin is a synthetic pentapeptide that stimulates growth hormone release by activating the ghrelin receptor. It is handled as a research tool rather than as a licensed therapeutic product. Its short chain length makes it comparatively simple to synthesize and analyze.
Both bind the same receptor, but ghrelin is a 28-amino-acid hormone with roles in appetite and energy balance. Ipamorelin is a much smaller synthetic peptide selected for growth hormone release with limited effect on appetite signaling in animal models. The full overlap between their effects is not completely mapped.
Most published data come from animal studies and a small number of human trials. Findings on growth hormone release are reasonably consistent, while long-term effects and direct comparisons with other secretagogues remain incompletely studied. Open questions include duration of action across different populations.
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.